Comparative Pharmacology
Head-to-head clinical analysis: DANTROLENE SODIUM versus ROBAXIN 750.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DANTROLENE SODIUM versus ROBAXIN 750.
DANTROLENE SODIUM vs ROBAXIN-750
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dantrolene sodium dissociates the excitation-contraction coupling in skeletal muscle by inhibiting calcium release from the sarcoplasmic reticulum via ryanodine receptor blockade.
Methocarbamol, the active ingredient in Robaxin-750, is a centrally acting muscle relaxant. Its precise mechanism is not fully understood, but it is believed to cause general central nervous system depression, possibly through inhibition of polysynaptic reflexes at the spinal cord level.
25 mg orally once daily for 7 days; then 25 mg three times daily for 7 days; then 50 mg three times daily for 7 days; then 100 mg three times daily. Maximum daily dose: 400 mg. For malignant hyperthermia: 1 mg/kg intravenously, may repeat up to cumulative dose of 10 mg/kg.
750 mg orally four times daily (total daily dose 3000 mg).
None Documented
None Documented
Terminal elimination half-life is approximately 8-10 hours in adults; may be prolonged to 12-15 hours in elderly or patients with hepatic impairment. Steady-state achieved in 3-4 days.
Terminal elimination half-life: 1-2 hours (methocarbamol); clinical context: short half-life necessitates frequent dosing (q6h) and may lead to fluctuating plasma levels.
Primarily hepatic metabolism; approximately 25% excreted in urine as metabolites, 45-50% in feces via bile; less than 1% unchanged in urine.
Renal: 90-95% as metabolites (mainly conjugated), <1% unchanged; biliary/fecal: minor; <2% eliminated in feces.
Category A/B
Category C
Skeletal Muscle Relaxant
Skeletal Muscle Relaxant